论文部分内容阅读
目的研究单唾液四己糖神经节苷脂钠注射液治疗糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)的疗效,以期为临床治疗提供一定的参考。方法选取2014年1月—2015年6月间入院诊治的DPN患者120例,随机分为实验组(60例)和对照组(60例)。实验组应用单唾液酸四己糖神经节苷脂钠注射液静脉滴注治疗,对照组应用甲钴胺肌肉注射。观察对比两组治疗效果、不良反应及治疗前后神经传导速度的改变。计数资料采用χ2检验,计量资料行t检验,P<0.05为差异有统计学意义。结果实验组患者经治疗后,感觉神经正中神经、尺神经、腓总神经及胫神经传导速度与治疗前[(40.2±2.9)、(46.4±3.9)、(36.4±2.1)、(44.5±5.2)、(33.5±3.2)、(41.2±3.0)、(30.0±2.2)、(36.2±3.1)m/s]比较,均有明显提高,运动神经正中神经、尺神经、腓总神经及胫神经传导速度较治疗前[(46.7±3.5)、(40.4±4.2)、(40.0±4.8)、(40.0±4.8)、(40.1±2.0)、(33.5±3.1)、(32.4±1.1)、(31.9±3.5)m/s]对比差异均有统计学意义(均P<0.05),对照组患者治疗后较治疗前也有明显提高,但提升程度明显低于实验组,对比差异均有统计学意义(均P<0.05)。实验组总有效率为96.67%,对照组总有效率为65.00%,两组对比差异有统计学意义(χ2=4.693,P<0.05)。实验组治疗期间出现皮疹3例,腹胀5例。对照组出现腹泻4例。两组患者不良反应均较轻微,可耐受。疗程结束后,两组均复查肝、肾功能,与治疗前相比并无显著变化。结论单唾液四己糖神经节苷脂钠注射液治疗糖尿病周围神经病变疗效显著、安全性高,并可有效改善患者的感觉与运动神经传导速度。
Objective To study the efficacy of mono-salicylic acid tetrahexose ganglioside sodium injection in the treatment of diabetic peripheral neuropathy (DPN), in order to provide some reference for clinical treatment. Methods 120 DPN patients admitted to hospital from January 2014 to June 2015 were randomly divided into experimental group (60 cases) and control group (60 cases). In the experimental group, monosialotetrahexosyl ganglioside sodium injection was administered intravenously, while in the control group, methylcobalamin was injected intramuscularly. Observed and compared the two groups of treatment, adverse reactions and changes in nerve conduction velocity before and after treatment. Counting data using χ2 test, measurement data t test, P <0.05 for the difference was statistically significant. Results After treatment, the sensory nerve median nerve, ulnar nerve, common peroneal nerve and tibial nerve conduction velocity were significantly different from those before treatment [(40.2 ± 2.9), (46.4 ± 3.9), (36.4 ± 2.1), (44.5 ± 5.2) ), (33.5 ± 3.2), (41.2 ± 3.0), (30.0 ± 2.2) and (36.2 ± 3.1) m / s, respectively. There was a significant increase in the median nerve, ulnar nerve, common peroneal nerve and tibial nerve The conduction velocity was significantly higher than that before treatment [(46.7 ± 3.5), (40.4 ± 4.2), (40.0 ± 4.8), (40.0 ± 4.8), (40.1 ± 2.0), (33.5 ± 3.1), (32.4 ± 1.1) ± 3.5) m / s] (all P <0.05). The patients in the control group were significantly higher than those before treatment, but the degree of improvement was significantly lower than that in the experimental group (all P <0.05) All P <0.05). The total effective rate was 96.67% in the experimental group and 65.00% in the control group. The difference between the two groups was statistically significant (χ2 = 4.693, P <0.05). 3 cases of rash during the experimental group during treatment, abdominal distension in 5 cases. Control group, 4 cases of diarrhea. Adverse reactions in both groups were mild and tolerable. After the course of treatment, liver and kidney function were examined in both groups, with no significant changes compared with those before treatment. Conclusion Single saliva tetrahexose ganglioside sodium injection for the treatment of diabetic peripheral neuropathy significant effect, high safety, and can effectively improve the patient’s sensory and motor nerve conduction velocity.